Published in Blood on August 12, 2013
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | NCT00114738
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 5.86
Targeting Bruton's tyrosine kinase in B cell malignancies. Nat Rev Cancer (2014) 1.76
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia (2014) 1.60
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov (2014) 1.22
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica (2014) 1.17
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica (2015) 1.10
Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood (2015) 1.01
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol (2014) 0.97
Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget (2014) 0.96
BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia (2015) 0.95
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML. Oncotarget (2014) 0.94
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget (2015) 0.88
Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J (2012) 0.87
Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features. Oncoscience (2014) 0.87
A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Ther Clin Risk Manag (2015) 0.87
Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control (2012) 0.86
Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. Oncotarget (2015) 0.84
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget (2015) 0.83
Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exp Hematol Oncol (2015) 0.82
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget (2015) 0.82
Bruton's tyrosine kinase promotes persistence of mature anti-insulin B cells. J Immunol (2014) 0.81
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci U S A (2015) 0.81
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia. Haematologica (2015) 0.80
Advances in treating chronic lymphocytic leukemia. F1000Prime Rep (2014) 0.79
Distinct patterns of B-cell receptor signaling in non-Hodgkins' lymphomas identified by single cell profiling. Blood (2016) 0.78
Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. Oncotarget (2015) 0.77
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia (2016) 0.77
The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy. Expert Rev Clin Immunol (2016) 0.77
PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Curr Top Microbiol Immunol (2016) 0.76
Targeting CXCL13 During Neuroinflammation. Adv Neuroimmune Biol (2015) 0.76
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk (2015) 0.76
CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. Oncoimmunology (2016) 0.75
Specificity and biologic activities of novel anti-membrane IgM antibodies. Oncotarget (2016) 0.75
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood (2016) 0.75
Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood (2016) 0.75
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
Homing and cellular traffic in lymph nodes. Nat Rev Immunol (2003) 7.23
A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature (2000) 6.89
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (2011) 5.98
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 5.86
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood (2007) 5.18
Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol (2004) 4.22
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood (2012) 4.17
The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood (2009) 3.56
Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas. J Histochem Cytochem (1980) 3.47
Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature (2002) 3.35
Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood (1999) 3.10
Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. J Exp Med (2002) 2.68
Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood (1997) 2.58
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther (2011) 2.48
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood (2010) 2.33
The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med (2003) 2.21
B-cell receptor signaling in chronic lymphocytic leukemia. Blood (2011) 2.11
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol (2006) 2.09
Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity (2007) 1.92
Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program (2011) 1.80
Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood (2002) 1.68
Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res (2009) 1.65
Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol (2012) 1.61
Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma (2002) 1.58
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood (2012) 1.45
CD38 and chronic lymphocytic leukemia: a decade later. Blood (2011) 1.33
Lymphoma dissemination: the other face of lymphocyte homing. Blood (2007) 1.31
Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med (2011) 1.29
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res (2009) 1.12
Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program (2012) 1.11
Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mayo Clin Proc (2004) 1.08
Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics (2009) 1.07
Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol (Dordr) (2011) 1.05
The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies. Semin Cancer Biol (2011) 1.04
CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. Chem Immunol (2000) 1.04
Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways. Haematologica (2012) 1.00
Signaling through murine CD38 is impaired in antigen receptor-unresponsive B cells. Eur J Immunol (1995) 0.99
New molecular targets in mantle cell lymphoma. Semin Cancer Biol (2011) 0.92
Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. Leukemia (2000) 0.92
Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer (2006) 0.92
The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood (2008) 0.89
CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. Semin Cancer Biol (2010) 0.82
CD38 in chronic lymphocytic leukemia: from bench to bedside? Mini Rev Med Chem (2011) 0.81
Over-expression of CCL3 MIP-1alpha in a blastoid mantle cell lymphoma with hypercalcemia. Eur J Haematol (2010) 0.79
A novel scoring system combining expression of CD23, CD20, and CD38 with platelet count predicts for the presence of the t(11;14) translocation of mantle cell lymphoma. Cytometry B Clin Cytom (2011) 0.78
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 7.57
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (2011) 5.98
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol (2012) 5.86
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood (2012) 4.17
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (2004) 3.31
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell (2012) 3.00
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet (2004) 2.79
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet (2003) 2.76
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol (2002) 2.74
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther (2011) 2.48
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A (2004) 2.46
Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med (2009) 2.42
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A (2009) 2.37
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol (2012) 2.36
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol (2008) 2.34
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood (2010) 2.33
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood (2012) 2.29
The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med (2003) 2.21
The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res (2010) 2.12
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood (2013) 2.03
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A (2007) 2.03
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood (2004) 2.01
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A (2013) 2.00
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res (2008) 1.95
Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity (2007) 1.92
Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma (2008) 1.90
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A (2003) 1.90
Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell (2011) 1.80
Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res (2008) 1.79
Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res (2002) 1.78
A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet (2013) 1.73
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood (2011) 1.72
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov (2014) 1.70
Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma (2011) 1.68
Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol (2012) 1.61
Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med (2014) 1.60
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood (2014) 1.58
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood (2012) 1.58
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J (2003) 1.57
Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett (2009) 1.56
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood (2010) 1.53
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell (2012) 1.52
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood (2002) 1.50
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood (2004) 1.48
Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppression. Pediatr Transplant (2003) 1.48
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma (2013) 1.42
Infection of mesothelial cells with human herpes virus 8 in human immunodeficiency virus-infected patients with Kaposi's sarcoma, Castleman's disease, and recurrent pleural effusions. Mod Pathol (2003) 1.40
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood (2008) 1.39
B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol (2013) 1.39
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest (2014) 1.38
Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med (2005) 1.32
Lymphoma dissemination: the other face of lymphocyte homing. Blood (2007) 1.31
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica (2009) 1.31
Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm (2006) 1.30
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood (2010) 1.30
Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J Hepatol (2005) 1.29
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood (2012) 1.27
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res (2012) 1.24
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am (2013) 1.22
Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One (2011) 1.21
The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. PLoS One (2010) 1.21
FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol (2007) 1.20
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res (2014) 1.19
Decitabine in older adults with acute myeloid leukemia: why was the dream broken? J Clin Oncol (2013) 1.19
miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest (2009) 1.16
Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood (2005) 1.16
CD44 is a macrophage binding site for Mycobacterium tuberculosis that mediates macrophage recruitment and protective immunity against tuberculosis. J Clin Invest (2003) 1.15
Fluorodeoxyglucose positron emission tomography in the presence of cardiac metastases. Clin Nucl Med (2003) 1.15
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res (2011) 1.14
Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc Natl Acad Sci U S A (2005) 1.14
The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer (2005) 1.13
Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. Eur J Biochem (2002) 1.13